|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 145.87 Million
|
|
Market Size (2030)
|
USD 199.17 Million
|
|
CAGR (2025-2030)
|
5.29%
|
|
Fastest Growing Segment
|
Open Angle Glaucoma
|
|
Largest Market
|
Kanto
|
Market Overview
Japan Glaucoma Drugs Market was valued at USD 145.87
Million in 2024 and is expected to reach USD 199.17 Million
by 2030 with a CAGR of 5.29% during the forecast period. The Japan glaucoma
drugs market is primarily driven by an aging population, increased prevalence
of glaucoma, and advancements in drug therapies. As Japan's population
continues to age, the incidence of glaucoma, a leading cause of irreversible
blindness, is rising, boosting the demand for effective treatments. Innovations
in drug development, including the introduction of new classes of medications
and combination therapies, are improving treatment outcomes and patient
adherence. Increased awareness and early diagnosis contribute to market growth
by driving the adoption of glaucoma drugs. Regulatory support for novel
therapies and a focus on personalized medicine further stimulate market
expansion. Enhanced access to healthcare and a growing emphasis on managing
chronic conditions also play significant roles in shaping the market dynamics.
Key Market Drivers
Increased Early Diagnosis
Increased early diagnosis of glaucoma are pivotal
drivers of the Japan glaucoma drugs market. Public health initiatives and
educational campaigns have been instrumental in elevating awareness about the
importance of regular eye exams and early detection of glaucoma. These
programs, spearheaded by government bodies, non-profit organizations, and
medical societies, have effectively communicated the risks associated with
glaucoma and the benefits of early intervention. The emphasis on routine eye
check-ups, particularly for individuals over 40 and those with risk factors
like family history or high intraocular pressure, has prompted a significant
shift in public behavior. By raising awareness, these initiatives encourage
more individuals to undergo regular eye examinations, leading to earlier
diagnoses and timely treatment of glaucoma. Early diagnosis is crucial as it
allows for prompt intervention, which can prevent or slow the progression of
the disease, thereby preserving vision and improving patient outcomes. This proactive
approach has resulted in increased prescriptions for glaucoma medications and
an expansion of the market. Advancements in diagnostic technologies, such as
optical coherence tomography (OCT) and automated visual field tests, have
further facilitated more accurate and earlier detection of glaucoma. These
technological improvements enhance diagnostic precision and enable healthcare
providers to identify the disease at its earliest stages, driving greater
demand for effective treatments. As a result, the combined impact of heightened
awareness, early diagnosis, and technological advancements is significantly
contributing to the growth of the Japan glaucoma drugs market.
Regulatory Support for New Therapies
Regulatory support for new therapies is a crucial
driver of the Japan glaucoma drugs market, significantly influencing the
development and availability of innovative treatments. The Japanese Ministry of
Health, Labour and Welfare (MHLW) plays a pivotal role in shaping the
regulatory landscape for pharmaceuticals, including glaucoma medications. By
establishing streamlined pathways for the approval and commercialization of
novel treatments, the MHLW facilitates the introduction of new drugs to the
market, thereby enhancing patient care and advancing therapeutic options. One
of the key elements of regulatory support is the framework for expedited
reviews and approvals. The MHLW offers fast-track procedures for drugs that
address unmet medical needs or provide significant improvements over existing
treatments. This expedited review process is designed to shorten the time
between drug development and market availability, allowing patients to benefit
from cutting-edge therapies sooner. For glaucoma drugs, which often need to
demonstrate both safety and efficacy in managing intraocular pressure and
preventing vision loss, such regulatory mechanisms are essential for bringing
innovative solutions to the market efficiently. On February 1, 2021, Santen
Pharmaceutical Co., Ltd. and Ube Industries, Ltd. announced that Santen
Pharmaceutical Korea Co., Ltd. officially launched EYBELIS Ophthalmic Solution
0.002% (generic name: Omidenepag Isopropyl) for the treatment of glaucoma and
ocular hypertension in South Korea. This launch follows the inclusion of
EYBELIS in Korea's national health insurance coverage.
In addition to expedited review processes, the MHLW
provides financial incentives to encourage investment in research and
development. These incentives may include subsidies, tax breaks, or grants
aimed at supporting the development of new therapies. By reducing the financial
burden associated with drug development, these incentives make it more feasible
for pharmaceutical companies to invest in the research and commercialization of
new glaucoma treatments. This supportive financial environment fosters
innovation and motivates companies to explore novel approaches to managing
glaucoma. The regulatory environment also includes mechanisms for conditional
approvals and adaptive licensing. These processes allow new drugs to enter the
market with conditional approval based on preliminary clinical data, with
further evidence required to confirm long-term safety and efficacy. Such
approaches are particularly beneficial for innovative treatments that show
promise but may still be undergoing final stages of clinical evaluation.
Conditional approvals enable timely access to new therapies while continuing to
monitor their performance and safety, thus bridging the gap between early
innovation and comprehensive clinical validation.
Growing Prevalence of Glaucoma
The growing prevalence of glaucoma in Japan is a
pivotal factor driving the expansion of the glaucoma drugs market. As Japan’s
population continues to age, the incidence of glaucoma, particularly primary
open-angle glaucoma (POAG), is experiencing a notable increase. This trend is
largely driven by the inherent risk factors associated with aging, as elderly
individuals are significantly more susceptible to developing glaucoma. The risk
of developing this sight-threatening condition escalates with age, making it a
major concern as the proportion of older adults in the population rises.
Japan’s demographic shift towards an aging
population has resulted in an increase in the number of individuals living into
advanced age. With longer life expectancies, there is a growing pool of
individuals at risk for glaucoma, a chronic and progressive eye disease that
requires ongoing management. The increase in the elderly population, coupled
with the extended lifespan of individuals, has led to a higher prevalence of
glaucoma. This expanding patient base is driving demand for a diverse range of
treatment options to address the varying needs of patients at different stages
of the disease. The growing prevalence of glaucoma has also spurred an increase
in screening and diagnostic efforts. With more individuals at risk, healthcare
systems are placing greater emphasis on regular eye exams and early detection
of glaucoma. Enhanced screening programs and the adoption of advanced
diagnostic technologies contribute to earlier identification of the disease,
allowing for timely intervention and management. Early diagnosis is crucial in
glaucoma management, as it enables the initiation of treatment before
significant optic nerve damage occurs, thus preserving vision and improving
patient outcomes.
Growing Awareness of Preventive Eye Care
Growing awareness of preventive eye care is
significantly contributing to the expansion of the Japan glaucoma drugs market.
In recent years, there has been a notable increase in public health campaigns
and educational programs dedicated to emphasizing the importance of regular eye
examinations and the early detection of glaucoma. These initiatives are
critical in educating both the general population and healthcare professionals
about the significance of proactive eye care and the potential risks associated
with glaucoma, a condition that often progresses silently but can lead to
irreversible vision loss if not managed effectively. Public health campaigns
have utilized various platforms, including television, radio, social media, and
community outreach programs, to disseminate information about glaucoma. These
campaigns often focus on educating individuals about the risk factors
associated with glaucoma, such as family history, age, high intraocular
pressure, and certain systemic conditions. By raising awareness of these risk
factors, the campaigns encourage people to undergo regular eye exams, which are
crucial for the early detection of glaucoma. Early detection allows for timely
intervention, which can significantly improve the management of the disease and
prevent or mitigate vision loss.
Educational programs have also been instrumental in
spreading knowledge about preventive eye care. These programs are often
implemented in collaboration with healthcare providers, schools, and community
organizations. They provide valuable information about the symptoms of
glaucoma, the importance of routine eye check-ups, and the availability of
effective treatments. By targeting both the general public and high-risk
groups, these programs help to build a culture of preventive care, making eye
health a priority for individuals and families. As awareness of the importance
of eye health and early intervention grows, there is a noticeable increase in
the number of individuals seeking eye screenings and timely treatment for
glaucoma. People are becoming more proactive about their eye health, driven by
the knowledge that early detection can lead to better management outcomes. This
shift in behavior results in higher diagnosis rates of glaucoma, as more people
are identified with the condition at earlier stages when treatment is most
effective. Consequently, the increased diagnosis rates lead to a greater demand
for glaucoma medications, as more patients require treatment to manage their
condition and prevent progression.
Advancements in Personalized Medicine
Advancements in personalized medicine are
significantly transforming the Japan glaucoma drugs market by introducing more
tailored and effective treatment strategies. Personalized medicine represents a
shift from the traditional "one-size-fits-all" approach to a more
individualized model of healthcare, where treatment plans are customized based
on a patient's unique genetic, environmental, and lifestyle factors. This
personalized approach enhances the precision of treatments, leading to improved
outcomes and better management of glaucoma, a complex and multifaceted eye
disease. Senju Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd.
announced the launch of AILAMIDE Combination Ophthalmic Suspension in Japan as
of June 16, 2020. Senju Pharmaceutical holds the marketing authorization, while
Otsuka Pharmaceutical collaborates on providing drug information related to
this new treatment. The primary, evidence-based approach to managing glaucoma
is the reduction of intraocular pressure. Treatment typically starts with a
single medication and may advance to combination therapy if necessary.
Utilizing combination ophthalmic solutions is crucial for improving patient
adherence and ensuring effective management of the condition.
One of the key drivers of this transformation is
the advancement in genetic research, which has identified specific biomarkers
associated with glaucoma. These biomarkers are genetic indicators that can help
in understanding the underlying mechanisms of the disease and its progression
in different patient populations. For example, genetic studies have revealed
variations in genes related to intraocular pressure regulation and optic nerve
health, which are critical in glaucoma pathogenesis. By identifying these
genetic markers, researchers and clinicians can develop targeted therapies that
address the specific biological pathways involved in an individual’s glaucoma.
This leads to the creation of drugs that are more effective in managing the
disease based on a patient's genetic profile. The integration of personalized
medicine into glaucoma treatment strategies allows for the development of
therapies that are tailored to the individual needs of patients. Personalized
treatment plans take into account factors such as genetic predispositions,
environmental exposures, and lifestyle choices, enabling healthcare providers
to select the most appropriate and effective therapies. For instance, patients
with specific genetic markers might benefit from novel drugs that target the
precise mechanisms responsible for their glaucoma, whereas others might require
different treatment approaches. This tailored approach not only enhances the
efficacy of treatments but also minimizes potential side effects by avoiding
medications that may not be suitable for a particular patient’s genetic makeup.
Download Free Sample Report
Key Market Challenges
High Cost of Advanced Glaucoma Therapies
One of the significant challenges facing the Japan
glaucoma drugs market is the high cost associated with advanced therapies. The
development and commercialization of novel glaucoma treatments, including new
drug formulations, sustained-release systems, and combination therapies, often
involve substantial investment in research and development. This investment
translates into higher prices for these advanced treatments. The financial
burden of such high-cost therapies can be a major barrier for both healthcare
providers and patients. For patients, the high cost of innovative glaucoma
drugs can lead to issues with accessibility and adherence. Even with health
insurance coverage, out-of-pocket expenses for cutting-edge treatments can be
prohibitively expensive for some individuals, particularly those on fixed or
lower incomes. This financial strain may result in patients opting for less
effective, more affordable treatments, potentially compromising their disease
management and overall quality of life. Healthcare providers and hospitals also
face challenges related to the cost of new glaucoma therapies. The adoption of
advanced treatments often requires adjustments in budgeting and resource
allocation. Hospitals may need to balance the use of expensive drugs with other
healthcare needs, which can be challenging in a constrained budget environment.
This cost pressure can also influence prescribing practices, with providers
potentially favoring cost-effective alternatives over more innovative but
expensive options.
The high cost of advanced therapies can create
disparities in treatment availability, particularly between urban and rural
areas. Patients in rural or less affluent regions may have limited access to
expensive treatments due to logistical and financial constraints, exacerbating
healthcare inequalities. This disparity can affect the overall effectiveness of
glaucoma management across different regions and patient populations. To
address these challenges, stakeholders in the Japanese healthcare system,
including pharmaceutical companies, insurers, and government agencies, need to
explore strategies to make advanced glaucoma therapies more affordable and
accessible. This could include negotiating drug prices, exploring
cost-effective delivery models, and providing financial assistance programs for
patients. Ensuring that innovative treatments are within reach for all patients
is crucial for improving disease management and achieving better health
outcomes.
Regulatory Hurdles and Approval Delays
Regulatory hurdles and approval delays represent
another significant challenge in the Japan glaucoma drugs market. The process
of bringing new glaucoma treatments to market in Japan involves navigating a
complex regulatory framework governed by the Ministry of Health, Labour and
Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA). This
regulatory environment, while ensuring the safety and efficacy of new
treatments, can also be a source of significant delays and obstacles. The
approval process for new glaucoma drugs often requires extensive clinical
trials, rigorous data analysis, and detailed documentation. These requirements
can extend the timeline for drug approval, leading to delays in making new
treatments available to patients. For pharmaceutical companies, navigating this
lengthy and detailed process can be resource-intensive and costly, potentially
impacting their decision to pursue drug development in Japan.
Regulatory agencies may have specific requirements
and standards that differ from those in other markets, such as the United
States or Europe. These differences can lead to additional complexities and
delays as companies work to meet the unique requirements of the Japanese
regulatory environment. The need for regulatory harmonization and streamlined
approval processes is essential to expedite the availability of new treatments
and reduce the burden on pharmaceutical companies. Approval delays can have
broader implications for patient care. Prolonged waiting times for new
treatments can result in patients missing out on potentially effective
therapies, which can negatively impact their disease management and overall
quality of life. The lack of timely access to innovative treatments can also
contribute to a sense of frustration and uncertainty among patients and
healthcare providers.
Key Market Trends
Expansion of Distribution Channels
The expansion of distribution channels is a
significant driver of the Japan glaucoma drugs market, playing a crucial role
in increasing the accessibility and availability of glaucoma medications. Over
recent years, there has been a notable growth in various distribution methods,
including online pharmacies and direct-to-consumer platforms, which have
revolutionized how patients obtain their medications. These modern distribution
channels offer unparalleled convenience and efficiency, which has a substantial
impact on market dynamics. Online pharmacies have emerged as a prominent
channel for distributing glaucoma drugs. These platforms allow patients to
order medications from the comfort of their homes, eliminating the need to
visit physical pharmacies. The convenience of online ordering is particularly
beneficial for individuals with mobility issues or those living in remote areas
where access to traditional pharmacies might be limited. Online pharmacies
often provide a broader selection of products, including both prescription and
over-the-counter (OTC) glaucoma medications. This expanded range ensures that
patients have access to various treatment options, including newer and
potentially more effective therapies, which can be crucial for managing
different stages and types of glaucoma.
Direct-to-consumer platforms also contribute
significantly to the expansion of distribution channels. These platforms, often
operated by pharmaceutical companies or their partners, offer a streamlined
approach for patients to purchase medications directly. By bypassing
traditional retail channels, direct-to-consumer models can provide a more
personalized experience, including tailored information about medication use,
potential side effects, and adherence support. This direct access can improve
patient engagement and adherence to prescribed treatments, which is essential
for managing chronic conditions like glaucoma. Partnerships between
pharmaceutical companies and distribution networks are instrumental in enhancing
the availability of glaucoma drugs across various regions. These collaborations
help ensure that medications are distributed efficiently and reach a wide
audience, including those in remote or underserved areas. By working with
established distribution networks, pharmaceutical companies can leverage
existing infrastructure and logistical expertise to overcome challenges related
to supply chain management. This ensures that patients across Japan, regardless
of their location, have access to necessary glaucoma treatments.
Technological Advancements in Drug Development
Technological advancements in drug development are
profoundly influencing the Japan glaucoma drugs market by introducing
innovative solutions that enhance both the efficacy and convenience of
treatments. These advancements are transforming traditional approaches to
managing glaucoma, leading to more effective therapies and improved patient
outcomes. Several key innovations are driving this transformation, including
sustained-release formulations, novel drug delivery systems, and combination
therapies.
One of the notable technological advancements is
the development of sustained-release formulations. These formulations are
designed to deliver medication gradually over an extended period, reducing the
frequency of dosing required. This not only improves patient adherence but also
enhances the overall effectiveness of the treatment. For patients with
glaucoma, who often need to manage their condition over many years,
sustained-release formulations offer a significant advantage by minimizing the
need for multiple daily doses and ensuring a more consistent therapeutic
effect. This innovation helps address one of the common challenges in glaucoma
management—maintaining patient compliance with prescribed regimens. Another
significant advancement is the introduction of novel drug delivery systems.
These systems include advanced devices and technologies that enhance the
targeted delivery of glaucoma medications. For example, drug-eluting implants
and microchips can be implanted in the eye to release medication directly to
the target area. Such systems can provide a more precise and controlled release
of drugs, potentially improving treatment outcomes and reducing side effects.
These innovations also offer convenience for patients, as they reduce the need
for frequent eye drops and other conventional delivery methods.
Segmental Insights
Indication Insights
Based on the Indication, open-angle
glaucoma is the dominant form, significantly overshadowing angle-closure
glaucoma in terms of prevalence and treatment demand. Open-angle glaucoma, also
known as primary open-angle glaucoma (POAG), is the most common type of
glaucoma globally and particularly prevalent in Japan due to its higher
incidence in aging populations. This form of glaucoma is characterized by a
gradual increase in intraocular pressure (IOP) as the drainage angle formed by
the cornea and iris remains open, but the trabecular meshwork becomes
obstructed over time. This obstruction impairs the outflow of aqueous humor,
leading to increased IOP and progressive damage to the optic nerve. The
dominance of open-angle glaucoma in the Japanese market can be attributed to
several factors. The aging population in Japan plays a crucial role. As people
age, the risk of developing open-angle glaucoma increases, which correlates
with the rising number of elderly individuals in the country. Statistics
indicate that the prevalence of open-angle glaucoma increases significantly
with age, making it a major concern for public health and a primary focus for
pharmaceutical companies developing glaucoma treatments.
In addition to demographic
factors, the nature of open-angle glaucoma contributes to its market dominance.
Unlike angle-closure glaucoma, which is less common but often presents as an
acute emergency, open-angle glaucoma develops slowly and often without
noticeable symptoms until significant optic nerve damage has occurred. This
asymptomatic progression leads to a higher rate of diagnosis and ongoing
management needs. Patients with open-angle glaucoma require long-term treatment
to control IOP and prevent further damage, resulting in a steady demand for
effective medications and therapies. The treatment landscape for open-angle
glaucoma is extensive, with various options available to manage the condition.
These include topical medications such as prostaglandin analogs, beta-blockers,
alpha agonists, and carbonic anhydrase inhibitors, which are commonly
prescribed to lower IOP and slow disease progression. Newer therapies and
combination drugs have been developed to enhance treatment efficacy and patient
adherence. The large market share of open-angle glaucoma is reflected in the
variety of drug formulations and delivery systems designed to cater to the
diverse needs of patients.
Drug Class Insights
Based on Drug Class, prostaglandin
analogs are the dominant class of medications, surpassing other therapeutic
options such as beta-blockers, alpha agonists, and carbonic anhydrase
inhibitors in both prevalence and market share. Prostaglandin analogs have
become the first-line treatment for managing intraocular pressure (IOP) in
patients with open-angle glaucoma, primarily due to their efficacy,
convenience, and favorable safety profile. Prostaglandin analogs, including
drugs such as latanoprost, bimatoprost, and travoprost, work by enhancing the
outflow of aqueous humor through the uveoscleral pathway. This mechanism
effectively lowers IOP, which is crucial in preventing damage to the optic
nerve and preserving vision. The popularity of prostaglandin analogs in the
market is attributed to several key factors. These drugs have demonstrated
superior efficacy in reducing IOP compared to other classes of glaucoma
medications. They are known for their potent IOP-lowering effects and long
duration of action, often providing once-daily dosing, which improves patient
adherence.
Another significant
advantage of prostaglandin analogs is their generally well-tolerated side
effect profile. While some patients may experience mild side effects such as
conjunctival hyperemia or increased pigmentation of the iris, these are
typically manageable and less severe compared to the systemic side effects
associated with beta-blockers. This favorable safety profile contributes to the
widespread use and preference for prostaglandin analogs among both healthcare
providers and patients.
Download Free Sample Report
Regional Insights
The Kanto region is the dominant player,
significantly influencing the market landscape compared to other regions such
as Hokkaido, Tohoku, Chubu, Kansai, Chugoku, Shikoku, and Kyushu. The Kanto
region, which includes major cities like Tokyo and Yokohama, serves as a
central hub for healthcare and pharmaceutical industries in Japan. This
prominence is reflected in the region’s substantial market share in glaucoma
drug sales and its pivotal role in shaping market trends.
Several factors contribute to Kanto's dominance in
the glaucoma drugs market. The region's large and densely populated urban
centers create a high demand for healthcare services, including specialized
treatments for conditions like glaucoma. Tokyo, as Japan's capital and one of
the largest metropolitan areas in the world, houses numerous prestigious
medical institutions, research facilities, and ophthalmology centers that focus
on the diagnosis and treatment of glaucoma. The concentration of healthcare
professionals and cutting-edge medical facilities in Kanto facilitates the
widespread availability and adoption of advanced glaucoma therapies. The Kanto
region benefits from its robust infrastructure and economic vitality, which
support the distribution and accessibility of glaucoma medications. Major pharmaceutical
companies and healthcare providers are headquartered or have significant
operations in Tokyo and its surrounding areas. This concentration of industry
players enhances the availability of both innovative and generic glaucoma
drugs, ensuring that a broad range of treatment options are accessible to
patients in this region. The presence of leading pharmaceutical firms also
drives market growth through research and development initiatives, contributing
to the development of new and effective glaucoma treatments.
The high standard of healthcare services and the
availability of specialized glaucoma care in Kanto contribute to a greater rate
of diagnosis and treatment initiation. With advanced diagnostic technologies
and well-established treatment protocols, patients in Kanto are more likely to
receive early and effective management for their glaucoma. This increased
diagnosis rate, coupled with a higher prevalence of glaucoma cases in an aging
population, drives the demand for glaucoma medications and contributes to the
region’s dominant market position. Kanto's economic prosperity and high
standard of living enable a higher level of healthcare expenditure among
residents. Patients in this region are more likely to have access to
comprehensive health insurance plans and the financial means to afford advanced
glaucoma treatments. This economic advantage supports the adoption of newer and
more expensive therapies, further cementing Kanto's leading role in the market.
Recent Developments
- According to a study
titled, “Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil
to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular
Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial
(J-ROCKET)”, Glaucoma is a major cause of blindness, affecting 64 million
people worldwide, with projections indicating this number will rise to 112
million by 2040. In Japan alone, approximately 4.65 million individuals are
impacted by this condition. Elevated intraocular pressure (IOP) is a
significant risk factor for glaucoma progression, and every millimeter of IOP
reduction is known to markedly delay disease advancement. This holds true not
only for patients with primary open-angle glaucoma (POAG) and elevated IOP but
also for those with normal-tension glaucoma (NTG). In a primary analysis
involving 245 patients, the least squares (LS) mean of diurnal IOP at Week 4
was 15.96 mmHg for the netarsudil 0.02% group and 17.71 mmHg for the ripasudil
0.4% group. This demonstrates that netarsudil 0.02% once daily (QD) was
superior to ripasudil 0.4% twice daily (BID) by a margin of −1.74 mmHg (p <
0.0001). The mean reduction from baseline in diurnal IOP at Week 4 was 4.65
mmHg for netarsudil 0.02% and 2.98 mmHg for ripasudil 0.4%. Adverse events
(AEs) were less common with netarsudil 0.02% compared to ripasudil 0.4%, with
ocular AEs occurring in 59.8% and 66.7% of patients, respectively. The most
frequently reported AE was conjunctival hyperemia, with incidences of 54.9% for
netarsudil 0.02% and 62.6% for ripasudil 0.4%. No serious eye-related AEs were
observed.
- According to a clinical
trial titled, “Evaluation of offset of conjunctival hyperemia induced by a
Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial”, in
patients with glaucoma who had been previously treated with anti-glaucoma eye
drops, conjunctival hyperemia triggered by the instillation of 0.4% ripasudil
appeared within 10 minutes. This hyperemia resolved within 2 hours
post-instillation, demonstrating that the redness induced by ripasudil was
transient in this group of patients.
- According to a study
titled, “Safety and efficacy of ripasudil in Japanese patients with glaucoma or
ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing
surveillance study”, in total, 3,359 patients (48% male, with a mean age of
69.1 ± 12.7 years) were assessed for safety, and 3,323 for efficacy. The
diagnoses included primary open-angle glaucoma (43.9%), normal-tension glaucoma
(36.6%), secondary glaucoma (8.7%), ocular hypertension (4.2%), and primary
closed-angle glaucoma (2.4%). The average observation period was 300.1 ± 122.4
days. By 12 months, 1,010 patients (30.1%) had discontinued ripasudil. Adverse
drug reactions (ADRs) were reported in 626 patients (18.6%), with the most
frequently occurring being conjunctival hyperemia and blepharitis.
Key Market Players
- AbbVie GK
- Novartis Pharma K.K.
- Eli Lilly Japan K.K..
- Kowa Company Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Santen Pharmaceutical Co., Ltd.
- CLEA Japan, Inc.
- Senju Pharmaceutical Co., Ltd.
- Kubota Pharmaceutical Holdings Co., Ltd.
- Shionogi Pharmaceutical Co., Ltd
|
By Indication
|
By Drug Class
|
By Distribution Channel
|
By Region
|
- Open Angle Glaucoma
- Angle Closure Glaucoma
- Others
|
- Prostaglandin Analogs
- Beta Blockers
- Alpha Agonist
- Carbonic Anhydrase Inhibitors
- Others
|
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
|
- Hokkaido
- Tohoku
- Kanto
- Chubu
- Kansai
- Chugoku
- Shikoku
- Kyushu
|
Report Scope:
In this report, the Japan Glaucoma Drugs Market has
been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Japan Glaucoma Drugs Market, By Indication:
o Open Angle Glaucoma
o Angle Closure Glaucoma
o Others
- Japan Glaucoma Drugs Market, By Drug Class:
o Prostaglandin Analogs
o Beta Blockers
o Alpha Agonist
o Carbonic Anhydrase Inhibitors
o Others
- Japan Glaucoma Drugs Market, By Distribution Channel:
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
- Japan Glaucoma Drugs Market, By Region:
o Hokkaido
o Tohoku
o Kanto
o Chubu
o Kansai
o Chugoku
o Shikoku
o Kyushu
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Japan Glaucoma Drugs Market.
Available Customizations:
Japan Glaucoma Drugs Market report with the
given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Japan Glaucoma Drugs Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]